Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Sandra Wymann"'
Publikováno v:
Biomolecules, Vol 13, Iss 10, p 1522 (2023)
Human complement receptor 1 (CR1) is a membrane-bound regulator of complement that has been the subject of recent attempts to generate soluble therapeutic compounds comprising different fragments of its extracellular domain. This review will focus on
Externí odkaz:
https://doaj.org/article/84acee268c14478fac815f3d72112852
Autor:
Anjan K. Bongoni, Ingela B. Vikstrom, Jennifer L. McRae, Evelyn J. Salvaris, Nella Fisicaro, Martin J. Pearse, Sandra Wymann, Tony Rowe, Adriana Baz Morelli, Matthew P. Hardy, Peter J. Cowan
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract The complement system is a potent mediator of ischemia–reperfusion injury (IRI), which detrimentally affects the function and survival of transplanted kidneys. Human complement receptor 1 (HuCR1) is an integral membrane protein that inhibi
Externí odkaz:
https://doaj.org/article/6759be9e51d64710ba80a5394b27e1b6
Autor:
Fabian Käsermann, David J Boerema, Monika Rüegsegger, Andreas Hofmann, Sandra Wymann, Adrian W Zuercher, Sylvia Miescher
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e37243 (2012)
It has been proposed that the anti-inflammatory effects of intravenous immunoglobulin (IVIG) might be due to the small fraction of Fc-sialylated IgG. In this study we biochemically and functionally characterized sialic acid-enriched IgG obtained by S
Externí odkaz:
https://doaj.org/article/7d8f17cd3e8b4fdaa764d0a96d1bda80
Publikováno v:
Journal of Immunological Sciences. 6:1-17
Human Complement Receptor 1 (CR1/CD35) is a potent negative regulator of the complement system. Its mechanism of action is through interaction with the complement activation fragments, C3b and C4b to mediate decay acceleration of the C3 and C5 conver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ef85c702a102d862613931393235e98
https://doi.org/10.29245/2578-3009/2022/4.1240
https://doi.org/10.29245/2578-3009/2022/4.1240
Autor:
Sandra Wymann, Marcel Mischnik, David Leong, Subhajit Ghosh, Xiahui Tan, Helen Cao, Benjamin Kuehnemuth, Glenn A. Powers, Partho Halder, Mitchell J. de Souza, Hannah S. James, Vesna Tomasetig, Holger Lind, Paolo Rossato, Catherine M. Owczarek, Saw Yen Ow, Steven K. Dower, Adriana Baz Morelli, Tony Rowe, Matthew P. Hardy
Publikováno v:
The Biochemical journal. 479(9)
Human Complement Receptor 1 (HuCR1) is a potent membrane-bound regulator of complement both in vitro and in vivo, acting via interaction with its ligands C3b and C4b. Soluble versions of HuCR1 have been described such as TP10, the recombinant full-le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df480786f0e2f3b18b1a8110b0b2493d
https://pubmed.ncbi.nlm.nih.gov/35470373
https://pubmed.ncbi.nlm.nih.gov/35470373
Autor:
Jennifer L. McRae, Matthew P. Hardy, Martin J. Pearse, Anjan K. Bongoni, Sandra Wymann, Peter J. Cowan, Tony Rowe, Ingela Vikstrom, Nella Fisicaro, Evelyn J Salvaris, Adriana Baz Morelli
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific Reports
The complement system is a potent mediator of ischemia–reperfusion injury (IRI), which detrimentally affects the function and survival of transplanted kidneys. Human complement receptor 1 (HuCR1) is an integral membrane protein that inhibits comple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda010c86c75a82e679913fb866698db
https://doi.org/10.1038/s41598-021-01423-y
https://doi.org/10.1038/s41598-021-01423-y
Autor:
Alphonse Hubsch, Abdulgabar Salama, Stefano Fontana, Orell Mielke, Vesselina Goranova-Marinova, Sandra Wymann, Billie L. Durn, Martin O. Spycher, John P. Lawo, Amgad Shebl
Publikováno v:
Transfusion. 57:2629-2638
BACKGROUND Patients treated with intravenous immunoglobulins (IVIG) rarely experience symptomatic hemolysis. Although anti-A and anti-B isoagglutinins from the product are involved in most cases, the actual mechanisms triggering hemolysis are unclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7e75242fe10184069364ce48c801e57
https://doi.org/10.1111/trf.14289
https://doi.org/10.1111/trf.14289
Autor:
Mitchell J. de Souza, Matthew P. Hardy, Martin J. Pearse, Kim G. Lieu, Saw Yen Ow, Martin O. Spycher, Anup G. Nair, Michael J. Wilson, Jason Simmonds, Yun Dai, Sandra Wymann, Adrian Zuercher, Anna Schnell, Con Panousis, Rebecca E. Butcher, Glenn A. Powers, Marcel Mischnik, Tony Rowe, Genevieve Martin-Roussety, Adriana Baz Morelli, Helen Cao, David Leong, Shirley Taylor
Publikováno v:
The Journal of Biological Chemistry
Human complement receptor 1 (HuCR1) is a pivotal regulator of complement activity, acting on all three complement pathways as a membrane-bound receptor of C3b/C4b, C3/C5 convertase decay accelerator, and cofactor for factor I-mediated cleavage of C3b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::605c43f8a6fc70ffcd57fb8866f643b1
https://doi.org/10.1074/jbc.ra120.016127
https://doi.org/10.1074/jbc.ra120.016127
Autor:
Annette Gaida, Nicole Spiegl, Alphonse Hubsch, Martin Imboden, Adriano Marques Antunes, Brigitte Zurbriggen, Simon Gerber, Sandra Wymann, Ibrahim El Menyawi
Publikováno v:
Biodrugs
Background Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the presence of antibodies to blood groups A and B (isoagglutinins) in the IVIG product. An immunoaffinity chromatograp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8366a5fa741d1c47525c949ea709a92a
https://doi.org/10.1007/s40259-016-0192-3
https://doi.org/10.1007/s40259-016-0192-3
Autor:
Martin Imboden, Liane Hoefferer, Adriano Marques Antunes, Annette Gaida, Isabelle Glauser, Brigitte Siani, Ibrahim El Menyawi, Reinhard Bolli, Katharina Willimann, Eleonora Widmer, Sandra Wymann, Martin O. Spycher
Publikováno v:
Transfusion. 55:S117-S121
BACKGROUND The passive transfer of antibodies specific to blood groups A and B (also called isoagglutinins) contained in immunoglobulin (Ig)G products for intravenous administration (IVIG) is believed to be largely responsible for rare but sometimes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b64557d01dabf20df687e12c73969ae8
https://doi.org/10.1111/trf.13088
https://doi.org/10.1111/trf.13088